Acute Myeloid Leukemia Medical Services in China

Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by the rapid proliferation and accumulation of abnormal, immature myeloid progenitor cells—blasts—in the bone marrow and peripheral blood. These malignant blasts impair normal hematopoiesis, leading to cytopenias (anemia, neutropenia, thrombocytopenia) and systemic consequences including infection, bleeding, and organ infiltration. AML arises from acquired somatic mutations in hematopoietic stem or progenitor cells, commonly involving genes such as FLT3, NPM1, CEBPA, IDH1/2, DNMT3A, and TP53. Pathogenesis involves a stepwise accumulation of genetic and epigenetic alterations that confer survival advantage, blocked differentiation, and uncontrolled self-renewal. Clonal evolution and microenvironmental dysregulation further contribute to treatment resistance and relapse. Epidemiologically, AML accounts for approximately 80% of acute leukemias in adults and has an annual incidence of 3–5 cases per 100,000 people in Western populations; incidence rises sharply after age 60, with median diagnosis age at 68 years. In China, age-standardized incidence is slightly lower (2.1–2.7 per 100,000), but absolute case numbers are substantial due to population size and aging demographics. Risk factors include prior exposure to ionizing radiation or chemotherapy (especially alkylating agents and topoisomerase II inhibitors), benzene and other industrial solvents, smoking, myelodysplastic syndromes (MDS), chronic myeloproliferative neoplasms, and inherited predisposition syndromes (e.g., Fanconi anemia, Down syndrome, RUNX1 familial platelet disorder). While most cases are sporadic, germline variants in genes like DDX41 and CEBPA are increasingly recognized. Quality of life (QoL) in AML is profoundly impacted—not only during intensive induction chemotherapy (with risks of sepsis, mucositis, prolonged hospitalization, and ICU admission) but also across survivorship phases. Fatigue, cognitive impairment ('chemo brain'), anxiety, depression, financial toxicity, and social isolation are prevalent. Long-term survivors may face infertility, secondary malignancies, cardiovascular complications, and persistent neurocognitive deficits. Supportive care—including psychosocial oncology, nutritional support, rehabilitation, and palliative integration—is integral to modern AML management. Early referral to specialized hematology centers significantly improves outcomes through risk-adapted therapy, access to clinical trials, and multidisciplinary expertise.

Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by uncontrolled proliferation and impaired differentiation of myeloid progenitor cells in the bone marrow and peripheral blood. Management requires rapid diagnosis, risk stratification, and multidisciplinary intervention led by hematology-oncology specialists. Treatment is broadly divided into induction, consolidation, and maintenance or targeted therapy phases, with decisions guided by age, performance status, cytogenetic and molecular profile (e.g., FLT3-ITD, NPM1, TP53, IDH1/2 mutations), and comorbidities.

Conservative treatment plays a critical supportive role throughout AML management but is not curative as monotherapy. It encompasses rigorous infection prophylaxis (e.g., fluoroquinolone or antifungal agents in neutropenic patients), transfusion support (leukoreduced red blood cells for hemoglobin <7–8 g/dL; platelet transfusions for counts <10 × 10⁹/L or active bleeding), tumor lysis syndrome (TLS) prevention (aggressive hydration, rasburicase or allopurinol, close electrolyte monitoring), and growth factor use—though granulocyte colony-stimulating factor (G-CSF) is generally avoided during induction due to theoretical concerns about leukemic blast proliferation. Nutritional support, psychological counseling, and symptom-directed palliative care are integral, especially for older adults or those unfit for intensive chemotherapy. For patients with contraindications to standard induction (e.g., severe cardiac, pulmonary, or hepatic dysfunction), low-intensity regimens such as azacitidine + venetoclax may serve as a bridge to supportive care or clinical trial enrollment.

Medication remains the cornerstone of AML therapy. Standard induction for fit patients (<60–65 years, good organ function) consists of '7+3' chemotherapy: cytarabine 100–200 mg/m² IV continuously for 7 days plus an anthracycline (idarubicin 12 mg/m² or daunorubicin 60–90 mg/m² IV on days 1–3). This achieves complete remission (CR) in ~60–80% of younger adults. Consolidation involves high-dose cytarabine (HiDAC; 3 g/m² IV every 12 hours on days 1, 3, and 5 for 2–4 cycles), which improves disease-free survival, particularly in favorable- and intermediate-risk groups. For adverse-risk AML—including complex karyotype, TP53 mutation, or therapy-related disease—allogeneic hematopoietic stem cell transplantation (allo-HSCT) is strongly recommended in first CR. Targeted agents have transformed precision management: FLT3 inhibitors (midostaurin, gilteritinib, quizartinib) are now standard-of-care—midostaurin combined with 7+3 improves overall survival in newly diagnosed FLT3-mutated AML, while gilteritinib is approved for relapsed/refractory FLT3-mutated disease. IDH1/2 inhibitors (ivosidenib, enasidenib) demonstrate durable responses in IDH-mutant AML, including in elderly or unfit patients. Venetoclax, a BCL-2 inhibitor, combined with hypomethylating agents (azacitidine or decitabine) or low-dose cytarabine, has become the preferred frontline regimen for patients ≥75 years or those with significant comorbidities, yielding CR rates of 60–70% and median overall survival exceeding 14 months. Other agents under investigation include menin inhibitors (e.g., revumenib) for KMT2A-rearranged or NPM1-mutant AML, and antibody-drug conjugates (e.g., vadastuximab talirine, though withdrawn due to toxicity, informs ongoing development).

Surgical treatment has no primary role in AML pathophysiology, as it is a systemic hematologic disorder without localized resectable mass. However, minor surgical procedures are routinely employed: bone marrow biopsy and aspiration (often bilateral iliac crest) for diagnosis, response assessment, and minimal residual disease (MRD) monitoring; central venous catheter placement (e.g., tunneled Hickman or PICC line) for safe administration of chemotherapy, transfusions, and parenteral nutrition; and occasionally lumbar puncture with intrathecal chemotherapy (e.g., cytarabine or methotrexate) in cases with suspected or confirmed central nervous system involvement—though CNS relapse is rare in AML (<5%). Allo-HSCT, while often categorized under medical oncology, involves procedural elements including stem cell harvest (from donor peripheral blood or bone marrow) and conditioning regimens (myeloablative or reduced-intensity), followed by infusion and post-transplant immune reconstitution management.

China offers distinct advantages in AML treatment delivery. First, the national healthcare system enables rapid access to standardized diagnostic workflows—including next-generation sequencing (NGS) panels for >50 AML-relevant genes—widely available at Tier-3 hospitals in Beijing, Shanghai, Guangzhou, and Chengdu, often within 5–7 working days. Second, China hosts one of the world’s largest repositories of real-world AML data, facilitating robust clinical research and regulatory approvals: the NMPA has granted priority review and accelerated approval for gilteritinib, ivosidenib, and venetoclax based on local phase II/III trials demonstrating efficacy comparable to global cohorts. Third, cost-effectiveness is notable—generic formulations of cytarabine, daunorubicin, and azacitidine are widely accessible, and biosimilar G-CSF reduces supportive care expenses. Fourth, China leads in allo-HSCT infrastructure: over 120 accredited transplant centers perform >10,000 transplants annually, with high donor availability via the China Marrow Donor Program (CMDP), now the world’s second-largest registry (>3.5 million donors). Finally, integrated traditional Chinese medicine (TCM) adjuncts—such as compound Kushen injection or Astragalus polysaccharide—are evidence-informed adjuvants used to mitigate chemotherapy-induced myelosuppression and improve quality of life, supported by randomized controlled trials published in journals like *Leukemia Research* and *Annals of Hematology*.

Recovery advice emphasizes longitudinal, patient-centered care. Patients should adhere strictly to scheduled follow-up visits (every 1–3 months for first year post-remission), including peripheral blood counts, bone marrow examinations, and MRD assessment via multiparameter flow cytometry or NGS-based assays. Vaccination status must be reviewed and updated post-chemotherapy or transplant (avoiding live vaccines for ≥24 months after allo-HSCT). Lifestyle modifications include strict hand hygiene, avoidance of raw seafood/unpasteurized dairy, and prompt reporting of fever (>38.0°C), bruising, or dyspnea. Nutritional guidance prioritizes high-protein, low-microbial-risk diets; physical rehabilitation (graded aerobic and resistance training) mitigates cancer-related fatigue and sarcopenia. Psychosocial support—including peer mentoring through organizations like the China Leukemia Foundation—and fertility preservation counseling (especially before alkylator-based conditioning) are essential components. Long-term survivors require surveillance for late effects: secondary malignancies, endocrine dysfunction (e.g., thyroid, gonadal), cardiovascular disease, and chronic graft-versus-host disease (cGVHD) in transplant recipients. With evolving therapeutic paradigms, 5-year overall survival now exceeds 65% for favorable-risk younger adults and approaches 35–45% for older patients receiving venetoclax-based regimens—underscoring the importance of timely referral to specialized hematology centers.